Yu-Chieh Wang serves as the Principal Scientist and Director of Emerging Platforms in Regenerative Medicine at Resilience US, Inc., where he spearheads innovative research and development programs aimed at overcoming critical challenges in human stem cell technologies. With over 15 years of extensive experience in...
Yu-Chieh Wang serves as the Principal Scientist and Director of Emerging Platforms in Regenerative Medicine at Resilience US, Inc., where he spearheads innovative research and development programs aimed at overcoming critical challenges in human stem cell technologies. With over 15 years of extensive experience in the fields of stem cell biology, cancer biology, and glycobiology, Yu-Chieh is at the forefront of advancing regenerative medicine. His work focuses on the intricate interplay between these disciplines, driving the development of complex medicines and cell therapies that hold the potential to transform patient care.
In his current role, Yu-Chieh leads an active R&D group dedicated to addressing the scientific bottlenecks associated with process and analysis development for human stem cells. His expertise in systems biology, RNA sequencing, and proteomics enables him to design and implement cutting-edge assays that facilitate translational research and discovery oncology. By leveraging his deep understanding of biochemistry and cell-based assays, he is committed to translating laboratory findings into viable therapeutic solutions.
Yu-Chieh's leadership in the Cell Therapy Franchise at Resilience is marked by his collaborative approach, fostering partnerships across multidisciplinary teams to accelerate the development of next-generation therapies. His passion for innovation and commitment to scientific excellence not only drive his team's success but also contribute to the broader mission of Resilience in creating transformative healthcare solutions. As the field of regenerative medicine continues to evolve, Yu-Chieh Wang remains a pivotal figure, dedicated to pushing the boundaries of what is possible in the realm of cell therapy and regenerative medicine.
